Fluorescence Imaging of Carcinoma During Breast Conserving Surgery

Breast Cancer Clinical Trial

Official title:

A Prospective Multi-center Clinical Study Evaluating the Use of PD G 506 A and the Eagle V1.2 Imaging System for the Visualization of Carcinoma During Breast Conserving Surgery

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04815083
• Other study ID #: SBI-CIP 20-002
• Status: Recruiting
• Phase: Phase 3
• Start date: April 27, 2021
• Est. completion date: June 2026

Study information

• Verified date: August 2022
• Source: SBI ALApharma Canada, Inc.
• Contact: Maeve Richmond
• Phone: (289) 800-9460
• Email: m.richmond[@]sbi-alapharma.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Breast conserving surgery (BCS) is performed on patients with breast cancer to resect and completely remove the cancer while conserving as much of the surrounding healthy tissue as possible. Current methods do not allow surgeons to determine the completeness of surgical resection in real-time. This often results in the need for a second surgical procedure, or in some cases more than two surgical procedures in order to have confidence that all cancer has been removed.

This Phase 3 study will evaluate the safety and efficacy of the fluorescent imaging agent PD G 506 A for the real-time visualization of cancer during standard of care breast conserving surgery. PD G 506 A is an investigational drug which is converted in the body into a fluorescent molecule that accumulates in cancer cells. Patients receiving PD G 506 A will undergo standard of care breast conserving surgery followed by fluorescence imaging and removal of any potentially cancerous tissue left behind in the surgical cavity.

Description:

Re-operations due to positive margins following breast conserving surgery (BCS) increase poor cosmesis, complications, discomfort, stress, adjuvant delay, medical costs and risk of local recurrence. Reducing positive margin rates can be achieved through optimizing surgical procedures. This study evaluates a new method for surgeons to visualize carcinoma in real-time, both in the surgical cavity and on the margins of excised specimen(s) during the index BCS procedure.

The active ingredient of PD G 506A is aminolevulinic acid hydrochloride (ALA HCl). ALA HCl is a prodrug that is metabolized intracellularly to form the fluorescent molecule protoporphyrin IX (PpIX). The exogenous application of ALA HCl leads to a highly selective accumulation of PpIX in malignant tissues.

This Phase 3, 2-part, single-blind [pathologist(s)-blinded] randomized placebo-controlled trial study is designed to evaluate the efficacy and safety of PD G 506 A to aid in the visualization of carcinoma during BCS. The Eagle V1.2 Imaging System will be used in this trial to visualize PpIX fluorescence.

Part A is an open-label training phase of the study to optimize workflow and Part B of the study is randomized and single-blind and will serve as the pivotal portion of the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 370
• Est. completion date: June 2026
• Est. primary completion date: May 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Female, 18 years or older

2. Histologically or cytologically confirmed primary breast cancer (includes invasive lobular carcinoma, invasive ductal carcinoma, inflammatory breast cancer, papillary breast cancer, adenoid cystic carcinoma of the breast, mucinous breast cancer, metaplastic breast cancer, cribriform carcinoma and ductal carcinoma in situ, alone or in combination with invasive disease)

3. Scheduled for a lumpectomy (including bilateral lumpectomy) of a breast malignancy (eligibility for breast conserving surgery/partial mastectomy based on clinical staging using TNM staging system (AJCC Cancer Staging Manual: Breast Cancer, 8th Edition70).

4. Patient must have normal organ and bone marrow function and be appropriate surgical candidate per site standard of care

5. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) starting the day entering the study, and for the duration of the study period (until the Week 2 visit)

Exclusion Criteria:

1. Currently on (neo)adjuvant therapy to treat another cancer

2. Receiving or intended to receive neoadjuvant therapy to treat the primary breast cancer (including chemotherapy, endocrine therapy and radiotherapy)

3. Stage 4 cancer, inclusive of metastatic disease

4. Non-invasive diseases of the breast (includes lobular carcinoma in situ, phyllodes and Paget's disease of the breast)

5. Patients who have had the following procedures performed on the involved breast:

1. Surgery for a benign lesion(s) within 1 year of the BCS date

2. Breast implants inserted within 1 year of the BCS date

3. Breast reduction, surgery for malignant disease or mastectomy (at any time prior to the BCS date)

4. Surgery for a benign lesion(s) or insertion of implants >1 year prior to the BCS date and who have signs of ongoing inflammation, active tissue healing and/or extensive scarring

5. Radiation at any time prior to the BCS date and who have signs of ongoing inflammation, active tissue healing and/or extensive scarring

6. Patients for whom intraoperative frozen section analysis is planned

7. Patients who have not recovered from adverse events due an investigational pharmaceutical or diagnostic agents administered more than 30 days prior to their scheduled surgical procedure

8. History of hypersensitivity to ALA HCl or porphyrins

9. Known or documented personal or family history of porphyria

10. Patient has a recording of any parameter as defined below:

1. Bilirubin: Above upper limit of normal

2. Aspartate aminotransferase (SGOT): > 2.5 X institutional upper limit of normal

3. Alanine aminotransferase ( (SGPT): > 2.5 X institutional upper limit of normal

11. Patient has serum creatinine >1.5 times institutional upper limit of normal, OR calculated creatinine clearance > 60 mL/min/1.73 m² for patients with creatinine levels above institutional normal.

12. Uncontrolled concurrent illness, that in the opinion of the Investigator would prevent the patient from participation in the study, including but not limited to:

1. Ongoing or active infection;

2. Cardiovascular disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia).

13. Patients who have the following collagen vascular diseases:

1. Lupus

2. Scleroderma

14. Use of an investigational drug within 30 days of their scheduled surgical procedure

15. Simultaneous use of other potentially phototoxic substances (such as St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones and tetracyclines), and topical preparations containing ALA for 24 hours during the perioperative period.

16. Social or medical situations including uncontrolled psychiatric illnesses that would in the opinion of the Investigator limit compliance with study requirements (e.g. ability to travel for follow-up)

17. Patients who are pregnant or become pregnant (it is unknown if ALA HCl is teratogenic or has abortifacient effects)

18. Patients who are breast feeding (there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ALA HCl, breastfeeding should be discontinued if the mother is treated with ALA HCl)

19. Inability to consent

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasm Female
• Breast Neoplasms

Intervention

Drug:
• Aminolevulinic Acid Hydrochloride
PD G 506 A for oral solution (aminolevulinic acid [ALA] hydrochloride [HCl] granules for oral solution) is administered as a single dose (20 mg/kg body weight) approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.

Device:
• Eagle V1.2 Imaging System
Fluorescence imaging camera and associated accessories used to view and capture fluorescence and white light images and videos of the surgical cavity and excised tissue specimens during the surgical procedure.

Drug:
• Placebo
Oral placebo is administered as a single dose approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.

Locations

Country	Name	City	State
United States	Montefiore Medical Center	Bronx	New York
United States	Aurora St. Luke's Medical Centre	Milwaukee	Wisconsin
United States	Orlando Health, Inc.	Orlando	Florida

Sponsors (1)

Lead Sponsor	Collaborator
SBI ALApharma Canada, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Positive margin conversion rate	Percentage of patients with negative-margins following fluorescence-guided resection (FGR) among patients with positive margins following standard of care (SoC)	2 weeks
Primary	Diagnostic performance (Specificity)	Patient-level specificity to identify residual carcinoma	2 weeks
Primary	Diagnostic performance (Sensitivity)	Patient-level sensitivity to identify residual carcinoma	2 weeks
Secondary	Orientation-level diagnostic performance	Orientation-level diagnostic performance of PD G 506 A-induced fluorescence to determine the presence or absence of cancer in the surgical cavity as compared to margin histopathology.	2 weeks
Secondary	Positive margin conversion rate among all patients	Percentage of patients with at least one histopathology-positive margin following SoC who then have ALL histopathology-negative margins following FGR, among all patients imaged.	2 weeks
Secondary	Patient-level diagnostic performance	Patient-level sensitivity, specificity, NPV, PPV of PD G 506 A-induced fluorescence to determine the presence or absence of residual cancer	2 weeks
Secondary	Patient-level diagnostic performance of PD G 506 A to detect residual cancer at the end of FGR with modified patient-level definitions	Patient-level sensitivity, specificity, PPV and NPV to determine the presence or absence of residual cancer in the surgical cavity at the end of FGR (using modified patient-level definitions)	2 weeks
Secondary	Patient-level diagnostic performance of PD G 506 A to detect cancer after SoC BCS	Patient-level sensitivity, specificity, PPV and NPV to determine the presence or absence of cancer in the surgical cavity after SoC BCS.	2 weeks
Secondary	Patient-level diagnostic performance of PD G 506 A to detect cancer after SoC with modified patient-level definitions	Patient-level sensitivity, specificity, PPV and NPV to determine the presence or absence of cancer in the surgical cavity after SoC (using modified patient-level definitions).	2 weeks
Secondary	Patient-level false negative rate of at the end of FGR	Percentage of patients assessed as residual tumor negative at the end of FGR who had positive final margins on histopathology	2 weeks
Secondary	Patient-level false positive rate	Percentage of patients in whom SOC final margins were carcinoma negative and all FL-driven shave specimens are carcinoma-negative	2 weeks
Secondary	Patients with carcinoma-negative margins after SoC found to have residual tumor following SoC that was identified with FL imaging	Percentage of patients with histopathology-negative margins at the end of SoC who have at least one orientation that was both FL-positive and histopathology-positive among (1) patients with histopathology negative final margins after SOC and (2) all patients imaged	2 weeks
Secondary	Patient-level true negative rate at the end of SoC	Percentage of patients with no fluorescence identified at the end of SoC in whom all final margins after SoC are histopathologically confirmed to be negative for carcinoma.	2 weeks
Secondary	Patient-level diagnostic performance to identify in vivo residual carcinoma after FGR	Patient-level in vivo diagnostic performance of PD G 506 A-induced fluorescence to determine the presence or absence of residual cancer in the surgical cavity at the end of FGR as compared to the final margin histopathology.	2 weeks
Secondary	Orientation discordant fluorescence status	Percentage of orientations where in vivo and ex vivo fluorescence assessments are discordant.	2 weeks
Secondary	Patient-level re-operation rate	Percentage of patients receiving a 2nd surgery on the ipsilateral breast within 1 year of index BCS to remove suspected residual disease.	1 year
Secondary	Patient-level early re-operation rate	Percentage of patients receiving an early 2nd surgery (planned or actual) on the ipsilateral breast related to positive final margins.	3 - 6 months
Secondary	Amount of tissue removed with FGR beyond SoC	Weight (mg) of all tissue removed based on SoC and/of FGR	2 weeks
Secondary	Patient satisfaction with breast	Patient satisfaction with the cosmetic outcome of breast conserving surgery performed based on SoC in combination with PD G 506 A and the Eagle V1.2 Imaging System	2 weeks, 3-, 6- and 12-months